探索SGLT2抑制剂对使用孟德尔随机化分析初级开角绿内障风险的影响
Yujin Guo1,2, Jing Zhao1, Shuai Hou3
1Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, China.
Scientific reports
|April 22, 2025
概括
抑制-葡萄糖共运输蛋白2 (SGLT2) 可能会降低初级开角玻璃眼 (POAG) 的风险. 这种效果似乎部分由较低的透析血压介导,这表明SGLT2抑制剂是潜在的POAG疗法.
科学领域:
- 眼科和遗传学 眼科和遗传学
- 药理学和心血管医学.
背景情况:
- 主要开角青光眼 (POAG) 是不可逆转失明的主要原因.
- -葡萄糖携带载体蛋白2 (SGLT2) 抑制剂用于管理2型糖尿病,并已显示出对心血管的益处.
- 抑制SGLT2对青光眼病原体的潜在影响仍然在很大程度上未被探索.
研究的目的:
- 调查SGLT2抑制与初级开角青光眼 (POAG) 风险之间的因果关系.
- 探索潜在的调解途径,包括代谢,血液动力学和炎症因素.
- 评估SGLT2抑制作为POAG的治疗策略的潜力.
主要方法:
- 一项针对药物的门德尔随机化 (MR) 研究,利用与SGLT2抑制相关的遗传变异.
- 分析结合了来自FinnGen联盟和多祖先全基因组关联研究的POAG遗传数据.
- 采用两步式MRI检查通过涉及肥胖,血压,脂质,氧化应激和炎症的途径进行调解.
主要成果:
- 基因预测的SGLT2抑制与POAG风险降低显著相关 (OR:0.28;P = 2.22 × 10-3),在验证队列中一致.
- 抑制SGLT2与有利的眼睛结构变化有关,包括光杯面积减少和光盘面积增加.
- 调解分析显示,透气血压部分调解了SGLT2抑制对POAG (4.8%) 的保护作用.
结论:
- 抑制SGLT2显示出一种潜在的因果保护作用,可以预防初级开角青光眼.
- 观察到的效果部分通过减轻腹压血压来调节.
- 抑制SGLT2代表POAG的一个有希望的治疗标,需要在大规模临床试验中进行进一步的研究.
相关概念视频
Open Angle Glaucoma: Treatment
358
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
358
Glucose Transporters
22.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.2K
Glaucoma: Overview
470
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
470
Dipeptidyl Peptidase 4 Inhibitors
125
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
125
Angle Closure Glaucoma: Treatment
374
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
374


